What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to formally announce Gilead Sciences' financial results for the third quarter ended September 30, 2023, and to provide investors with access to the related press release.

Where can I find the detailed financial results for Q3 2023?

The detailed financial results, including both GAAP and non-GAAP measures, are provided in the press release filed as Exhibit 99.1 to this 8-K. You should refer to that press release for specific numbers and performance details.

What is the difference between GAAP and non-GAAP measures, and why does Gilead present both?

GAAP (Generally Accepted Accounting Principles) are standard accounting rules. Non-GAAP measures are adjustments to GAAP results that management believes offer a more useful view of the company's ongoing operational performance. Gilead presents both because management uses non-GAAP measures internally for budgeting and planning, and believes they can be useful supplements for investors. A reconciliation between GAAP and non-GAAP figures is available in the press release.

Is this 8-K filing considered 'filed' for liability purposes under the SEC?

No, the information provided in Item 2.02 and Item 9.01 of this 8-K filing, including Exhibit 99.1, is furnished rather than filed. This means it is not subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, nor is it automatically incorporated by reference into other SEC filings.

GILD 8-K: Earnings & Results

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on November 7, 2023, to announce its third-quarter financial results for the period ending September 30, 2023. The filing primarily directs investors to a press release (Exhibit 99.1) containing detailed financial performance data, including both GAAP and non-GAAP measures. Management believes that the non-GAAP information provides useful insights for investors as it is used internally for operational and financial planning. Investors are encouraged to review the press release and the accompanying reconciliation of GAAP to non-GAAP financial measures for a comprehensive understanding of the company's performance. The press release itself will contain the specific figures regarding revenue, profitability, and any forward-looking guidance. While this 8-K filing does not provide the direct financial numbers, it serves as the official notification and access point to the third-quarter earnings report, allowing investors to assess the company's recent performance and outlook.

Key Highlights

1Gilead Sciences announced its third-quarter 2023 financial results via an 8-K filing on November 7, 2023.
2The filing includes a press release (Exhibit 99.1) with detailed Q3 2023 financial performance.
3Both GAAP and non-GAAP financial measures are presented in the press release.
4Management utilizes non-GAAP financial information for internal operational and financial planning purposes.
5Investors are advised to consult the press release for specific financial results and the reconciliation of GAAP to non-GAAP measures.
6The information furnished in this 8-K is not considered 'filed' for certain SEC provisions, limiting liability under Section 18 of the Exchange Act.

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Nov 7, 2023)

Summary

Key Highlights

Frequently Asked Questions